Article Text
Declarations of Interest
P154 Safety of tiotropium in pre-school children with symptomatic persistent asthma
Abstract
H Bisgaard has been a consultant for AstraZeneca, Boehringer Ingelheim and Chiesi;
M Vandewalker has received research grants and personal fees from Boehringer Ingelheim;
L Graham made no relevant disclosures;
P Moroni-Zentgraf is an employee of Boehringer Ingelheim;
M Engel is an employee of Boehringer Ingelheim;
G El Azzi is an employee of Boehringer Ingelheim;
SD Vulcu is an employee of Boehringer Ingelheim;
H Finnigan is an employee of Boehringer Ingelheim;
EJLE Vrijlandt has received personal fees from Boehringer Ingelheim